Kornimate/medical-research-clean huggingface dataset:
sgb in management of patients with pdph using tcd

Conditions: Post-Dural Puncture Headache

Summary: this study aims to investigate the ability of spgb in the management of pdph. transcranial doppler is also used as an measure to assess the block success by detecting the variability in the cerebral hemodynamics before and after the block.

this clinical trial is performed in postoperative orthopedic unit. in this study, 120 patients were enrolled who had an epidural anesthesia; 60 patients who developed pdph joined the treatment group (a) and received the sp block. they are assessed before the procedure by nrs and at 30 mins, 2h, 4h, 6h, 12h, and 24h after the procedure. patients are also assessed by tcd before and after the block. the control group (b) included 60 patients with no pdph.

Eligibility criteria:
inclusion criteria: * patients are considered who had an epidural anesthesia * patients with asa 1 and 2 * patients' age ranged from 18 to 60 years. exclusion criteria: * patients with septal perforation, nasal septum deviation,or nasal bleeding. * patients have recent nasal trauma * patients have recent nasal surgery * patients have a nasal infection * patients within asa 3 and 4 * patients older than sixty yrs or younger than eighteen yrs.

Keywords: accidental dural puncture post dural puncture headache sphenopalatine ganglion block transcranial doppler
disorders of sexual development and gonadal tumor risk

Conditions: Disorders of Sexual Development

Summary: disorders of sexual development are rare and represent a spectrum of heterogeneous pathologies. the risk of developing a malignant gonadal germ cell tumor (mgct) exists and varies according to the etiology. the indication for prophylactic gonadectomy must be modulated and discussed for all patients. it is essential to assess each patient's individual risk. the aim of our study is to assess gonadal tumor risk in patients with disorders of sexual development according to etiology the primary objective is to evaluate tumor risk and the indication for gonadectomy in cases of disorders of sexual development according to etiology. the secondary objectives are to evaluate the timing of gonadectomy, to monitor changes in practice over time, and to assess the contribution of imaging and/or biological tests to tumor detection.


Eligibility criteria:
inclusion criteria: * patients who underwent gonadectomy for variation in genital development between 1990 and 2022. * pathological anatomy examination in lyon * with clinical data * with karyotype * 3 categories: * with genetic diagnosis * without genetic diagnosis because searched but not found * without genetic diagnosis because not searched exclusion criteria: * biopsies without gonadectomy * fetus * operated outside the period 1990-2022 * lack of clinical data * no karyotype

Keywords: surgery pediatrics urology endocrinology gonadoblastoma dysgerminoma neoplasms gonadal tissue sexual development oncology gonadal dysgenesis androgen-insensitivity syndrome testicular regression syndrome anti-mullerian hormone
computed tomography (ct) reconstruction for axillary lymph node structure

Conditions: Invasive Breast Cancer

Summary: this is a prospective, single-center, non-randomized, non-controlled observational study.

the negative predictive value of ultrasound for lymph node with neoadjuvant chemotherapy is low, magnetic resonance imaging (mri) or pet/ct did not significantly improve specificity to axillary lymph node. the aim of this study is to determine performance of computed tomography (ct) reconstruction on evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients.

Eligibility criteria:
inclusion criteria: * invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration (fna) or core needle biopsy (cnb). * underwent computed tomography (ct) reconstruction for assessment of axillary lymph node status before and after neoadjuvant chemotherapy (nac). * attend the study voluntarily, sign the informed consent. exclusion criteria: * contradiction for adjuvant chemotherapy. * contradiction for proceeding surgery.

Keywords: computed tomography (ct) reconstruction axillary lymph node status
a study of bind-014 in patients with urothelial carcinoma, cholangiocarcinoma, cervical cancer and squamous cell carcinoma of the head and neck

Conditions: Urothelial Carcinoma; Cholangiocarcinoma; Cervical Cancer; Squamous Cell Carcinoma of Head and Neck

Summary: bind-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck. ferumoxytol imaging will also be investigated at us sites as an exploratory endpoint.


Eligibility criteria:
inclusion criteria: 1. diagnosis of advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree or squamous cell carcinoma of the head and neck. 2. progressive disease after ≥ 1 prior chemotherapy regimen. 3. patients with brain metastases are eligible if asymptomatic and neurologically stable for at least 4 weeks and are not taking any medications contraindicated 4. chemotherapy must have been completed at least 4 weeks prior to initiation of study medication 5. ecog performance status 0-1 6. tumors must have measurable disease as per recist (version 1.1); 7. female or male, 18 years of age or older 8. adequate organ function 9. life expectancy of \> 3 months exclusion criteria: 1. current treatment on another therapeutic clinical trial 2. prior treatment with docetaxel within 6 months of enrollment 3. stage ii, iii or iv cardiac failure 4. carcinomatous meningitis 5. ongoing cardiac dysrhythmias 6. peripheral neuropathy 7. serious concomitant conditions 8. pregnant or breast feeding 9. known sensitivity to ferumoxytol 10. hypersensitivity to polysorbate 80
analysis of naïve patients with age-related macular degeneration neovascular type and treated with ranibizumab (lucentis®) in treat-and-extend at the chu brugmann.

Conditions: Macular Degeneration

Summary: age-related macular degeneration (amd) is a leading cause of blindness in people over 50 years old. neovascular amd, the most severe form and the most severe is characterized by the appearance, spread and growth of subretinal neovessels. one of the major molecular mediators is the endothelial growth factor vascular (vegf). intra-vitreous (ivi) injection of an anti-vegf may slow the progression of neovascular amd and stabilize vision in the majority of cases. ranibizumab (lucentis®) is one of the anti-vegf molecules approved in belgium to treat neovascular amd. at the start of its use, ranibizumab was first injected monthly and then according to the "reactive" protocol. over time, a new strategy of treatment was born: the "treat-and-extend" (t\&e). this is 'made to measure' protocol for each patient aiming to reduce the frequency of injections while guaranteeing inactivity of the disease. it starts with the loading dose, i.e. 3 injections given 4 weeks apart. subsequently, the interval is lengthened by slices of 1 or 2 weeks provided that the visual and anatomical results remain stable. in the event of deterioration, the interval is shortened while keeping a minimum of 4 weeks between each iiv. the efficacy and safety of ranibizumab, when used in a proactive regimen of t\&e, has been shown in the cantreat randomized controlled trial. however, there is a lack of more data on t\&e used in current practice, and particularly on the number of injections and treatment intervals over a minimum treatment period of 24 months. the aim of this retrospective study carried out at the chu brugmann hospital is to determine the number of injections and the intervals necessary to have encouraging results in visual acuity over a treatment period of at least two years.


Eligibility criteria:
inclusion criteria: * patients\> 50 years old diagnosed with neovascular age related macular degeneration, * patients who have never received anti-vegf treatment, * patients who started intra-vitreous injections of ranibizumab between 01 january 2014 and november 30, 2019, * treatment by "treat-and-extend" directly after the loading dose of ranibizumab, * availability of the medical file reporting treatment with ranibizumab. exclusion criteria: * participation in an interventional clinical study during treatment with ranibizumab, * patients suffering from ocular pathologies and having required surgery during the first 24 months of treatment with ranibizumab (for example advanced glaucoma or cataract).
chemoradiotherapy in esophageal or esophagogastric junction cancer

Conditions: Esophagus Cancer; Esophagogastric Junction Cancer; Chemoradiation; Targeted Therapy; Immunotherapy; Chemotherapy Effect

Summary: definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. a multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. morerover, molecular targeting agents does not show clear efficacy in ec up to now. nowadays, the pace of development of cancer immunotherapies is accelerating. clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. there have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. the purpose of this study was to explore the optimal treatment modalities including pd-1/pd-l1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.


Eligibility criteria:
inclusion criteria: * ≥18 years； * esophageal or esophagogastric cancer； * histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as i-iva(ajcc 8th)； * primary treatment performed in cancer hospital, chinese academy of medical sciences； * ecog ps score: 0\~1； * estimated survival time ≥3 months； * normal organ and marrow function as defined below:hemoglobin: greater than or equal to 100g/l ;leukocytes: greater than or equal to 4,000 g/l; neutrophil: greater than or equal to 2,000 g/l; platelets: greater than or equal to 100,000/mm3 ; creatinine: less than or equal to 1.5 times the upper limit or ccr greater than or equal to 60 ml/min; ast/alt: less than or equal to 2.5 times the upper limit; total bilirubin: less than or equal to 1.5 times the upper limit; inr: less than or equal to 1.5 times the upper limit; aptt: less than or equal to 1.5 times the upper limit; pt: less than or equal to 1.5 times the upper limit； * informed consent； exclusion criteria: * with any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, cns, etc； * patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer； * existing active infection such as active tuberculosis and hepatitis； * history of myocardial infarction within the past 6 months or history of ventricular arrhythmia； * uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness history of allergic reactions attributed to paclitaxel, albumin or cisplatin； * participation in other clinical trials currently or within 4 weeks of selection； * pregnant or lactating females； * absence of medical records.
hepatitis c virus (hvc) positive heart grafts in hcv negative recipients

Conditions: Heart Failure

Summary: to provide proof-of-concept data on the efficacy/safety of transplanting hcv positive donor grafts in hcv negative heart recipients who are currently listed.


Eligibility criteria:
inclusion criteria: * male or female * age 18 and older * active on the transplant list * donor organ with antibody and nat (nucleic acid test) positive for hcv * hcv negative recipient; this includes patients who never had hcv and those with hcv previously eradicated with antiviral therapy. the latter is defined as those with undetectable hcv viral load at least 3 months since stopping therapy. * willing and able to provide written informed consent or for those subjects where hepatic encephalopathy affects their ability to provide initial or ongoing consent, has an appropriate and legally-authorized representative willing and able to provide consent on behalf of the subject * patients listed for multiple organ transplant (heart and kidney or heart and liver) can be included based on agreement of non-cardiac organ transplant team exclusion criteria: * participants co-infected with hiv * donor previously treated with an ns5a containing regimen (if treatment history of donor known) * known allergies or hypersensitivity to daa or ribavarin * pregnancy and/or actively breastfeeding

Keywords: hcv
enhance wellness for individuals with long-term physical disabilities

Conditions: Multiple Sclerosis; Muscular Dystrophy; Post-polio Syndrome; Spinal Cord Injury

Summary: this project is an adaptation trial, testing the efficacy of an evidence-based community wellness program, enhance wellness (http://www.projectenhance.org/enhancewellness.aspx), in a sample of middle and older-aged adults living with multiple sclerosis, spinal cord injury, post-polio syndrome and muscular dystrophy.

this is a quasi-experimental project, comparing the effects of enhance wellness in a sample of adults aged 45 years or older and living with long-term physical disability, to two quasi-control groups: a sample of adults without long-term disability participating in enhance wellness, and a sample of adults with long-term disability not participating in enhance wellness. outcomes are collected pre-intervention and post-intervention, approximately 6-months apart.

Eligibility criteria:
inclusion criteria: * multiple sclerosis, muscular dystrophy, post-polio syndrome, or spinal cord injury diagnosis (group 1 and 3) * living in king county, washington (group 1 only) * ability to read and understand english exclusion criteria: * active suicidal ideation * requires the use of a mechanical ventilator to breathe or speak
exercise and neural response to food cues in children

Conditions: Exercise Condition (EX); Control Session (CON)

Summary: physical exercise has been shown to significantly reduce subsequent energy intake in obese adolescents but not in lean, without altering their appetite feelings. although previous studies have pointed out the role of gastric peptides in this post exercise nutritional response, some recent work question the role of the neural system in the post exercise drive to eat. this study tends to explore whether or not an acute bout of exercise can affect the neural response to food cues in adolescents, obese or lean.

after a medical inclusion, the adolescents will have to realise a dxa to assess their body composition and a submaximal exercise to evaluate their aerobic capacities. they will have then to enter the laboratory on 2 different occasions in a randomized order from 8am to 330pm: at 8am they will receive a calibrated breakfast. then, at 1045; they will have to complete one of the experimental condition: 1) a cycling exercise or 2) remaining sitting fpr one hour. after the one hour sitting station or the exercise bout, they will be asked to complete a computer task while and electroencephalogram will be recorded. this computer task consists in visual recognition of rare pictures compared to frequent ones (oddball method). at 1215 they will be offered ad libitum meals. at regular intervals through the day, their appetite feelings will be assessed using visual analogue scales. ad libitum energy consumption will be assessed by investigators and recorded for each participants.

Eligibility criteria:
inclusion criteria: * male * 12-15 years old * bmi defining obesity (cole et al., 2000) * not being under diet restriction * information and consent forms have to be signed by the adolescent and his legal representative * being registered to the national social security system exclusion criteria: * being under medication * contraindication to exercise * smokers * dieting
a comparative study of zg-801 and placebo in patients with hyperkalemia

Conditions: Hyperkalemia

Summary: the purpose of this study is to evaluate the superiority of zg-801 to placebo in japanese hyperkalemia patients whose serum potassium value becomes normal in the run-in period by comparing the change in the value at the double-blind period week 4, and to further evaluate the efficacy and safety of zg-801 in japanese hyperkalemia patients administrated zg-801 for maximum 9 weeks.


Eligibility criteria:
inclusion criteria: * patients whose serum potassium value (local) at the run-in period baseline is ≥5.5meq/l, \< 6.5 meq/l * age 20 - 80 years old at informed consent * patients who understand an overview of the study and voluntarily consented to participate in the study by documents. main exclusion criteria: * patients determined to require emergency treatment for hyperkalemia at the run-in period baseline * patients with poorly controlled blood pressure * patients with heart failure in new york heart association class iv * patients who have experienced heart transplant, liver transplant or kidney transplant or who are predicted that the need for them will occur during the study * patients who have taken any of the following medication within 7 days prior to the run-in period baseline or currently administrated. 1. sodium polystyrene sulfonate 2. calcium polystyrene sulfonate 3. sodium zirconium cyclosilicate hydrate 4. potassium supplement * patients with or who have experienced a severe swallowing disorder, moderate to severe gastroparesis, severe constipation, bowel obstruction, incarceration, abnormal post-operative bowel motility disorders or severe gastrointestinal disorders. in addition, patients who have experienced bariatric surgery or major gastrointestinal surgery (e.g., bowel resection). * patients suspected to be with transient high potassium value.(ex. caused by dietary effects only)
three doses of hepatitis a vaccine in patients with immunomodulating drugs

Conditions: Vaccine Response Impaired

Summary: hepatitis a vaccine is the most frequently used traveler's vaccine, yet data on its ability to induce protective immunity in immunosuppressed travelers are scarce. the investigators assess the hepatitis a virus (hav) antibody response in patients with rheumatoid arthritis (ra) treated with tumor necrosis factor (tnf) - inhibitors and/or methotrexate (mtx). in a previous study, 2 doses were not considered effective and there is therefore need for a study with an additional dose

methods: parameters registered at baseline were: age, sex, duration of disease, medications, activity of disease (visual analogue scale), health assessment questionnaire disability index, disease activity score, acute phase reactant and total immunoglobulin g in plasma). hepatitis a vaccine (epaxal or havrix) were given at 0 and 6 months. hepatitis a virus (hav) antibodies is measured before vaccination and at month 1, 6 (before dose 2), 7 and 12 with quantitative hav igg, using the havab-igg architect system, and by the havab 2.0 assay on the axsym machine from abbott. the level of protective immunity to hav is defined as hav igg \> 10miu/ml.

Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis * tnf-alfa blocker and / or methotrexate in use as a medication against ra * a desire to get protected against hepatitis a * men and women age 18-65 years * written informed consent * women of childbearing potential must use effective contraception - exclusion criteria: * treatment with rituximab within 9 months before study start * known previous hepatitis a infection * previous vaccination against hepatitis a * allergy to eggs or formaldehyde * pregnancy or lactation * excessive use of alcohol * mental retardation * acute disease at the time of examination (fever \> 38 degrees) * volunteer works as an employee of the researchers * previous vaccination against hepatitis a * egg-, hen-protein- or formaldehyde allergy * pregnancy or lactation * excessive use of alcohol * another vaccine given within a month * acute disease at the time of examination (fever \> 38 degrees) * not suitable for other reason in the investigator's opinion (other serious disease, i.e. aids/hiv-positive, cancer with ongoing cytostatic treatment)

Keywords: hepatitis a vaccine tnf-alfa inhibitory drugs rheumatoid arthritis methotrexate
comparison of the effect of ondansetron and combined ondansetron and betahistine on postoperative nausea and vomiting after gynecological laparoscopy

Conditions: Nausea and Vomiting

Summary: many patients undergoing gynecologic laparoscopic surgery experience postoperative nausea and vomiting (ponv) despite prophylaxis and treatment with ht3 receptor antagonists such as ondansetron. involvement of multiple types of receptors and factors may be a reason for inadequate control of ponv with a single agent. betahistine, a histamine antagonist at h1 receptor and antagonist at h3 receptor, is widely used as a treatment of dizziness. dizziness is one of the cause of nausea and vomiting. this study is to compare the effects of ondansetron and combined ondansetron and betahistine in preventing ponv in high-risk patients receiving intravenous opioid-based patient-controlled analgesia (iv-pca) after gynecological laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * patient scheduled for elective gynecological laparoscopic surgery * american society of anesthesiologists physical class i, ⅱ, between the ages of 20 and 70 years exclusion criteria: * hepatorenal disease * bmi \> 35 kg/m2 * allergy to ondansetron or betahistine * gastrointestinal disease * vomiting within 24h * administration of antiemetics or opioids within 24h * qt prolongation (qtc \> 440ms) * pheochromocytoma * pregnant * problem with communication